Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$106.98 USD

106.98
4,386,467

-1.72 (-1.58%)

Updated Oct 21, 2024 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially

Nalak Das headshot

Three Encouraging News on U.S. Economic Recovery: 5 Top Picks

by Nalak Das

We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.

Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track

by Zacks Equity Research

Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3

by Zacks Equity Research

Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.

Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter. Stock declines in pre-market.

Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.

Sanghamitra Saha headshot

5 ETFs Strategies to Play in November

by Sanghamitra Saha

November kicked off on a solid note after a solid October rally. Better-than-expected corporate earnings boosted the U.S. stocks.

    Exelixis (EXEL) Misses on Q3 Earnings & Revenues, Tweaks View

    by Zacks Equity Research

    Exelixis (EXEL) misses on earnings and revenues in the third quarter. Both figures increase on a year-over-year basis.

    The Zacks Analyst Blog Highlights: PayPal, Merck, Caterpillar, Cisco Systems and TJX Companies

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: PayPal, Merck, Caterpillar, Cisco Systems and TJX Companies

    Sheraz Mian headshot

    Top Analyst Reports for PayPal, Merck & Caterpillar

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc. (PYPL), Merck & Co., Inc. (MRK), and Caterpillar Inc. (CAT).

    Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

    by Zacks Equity Research

    Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

    ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag

    by Zacks Equity Research

    ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

    ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag

    by Zacks Equity Research

    ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. The company lowers its operating expense guidance for 2021.

    Will Merck (MRK) Gain on Rising Earnings Estimates?

    by Zacks Equity Research

    Merck (MRK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Investor focus is likely to be on the sales outlook for Moderna's (MRNA) authorized coronavirus vaccine on the third-quarter earnings call.

    Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up

    by Zacks Equity Research

    Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.

    Kinjel Shah headshot

    Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

    by Kinjel Shah

    Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

    Company News for Oct 29, 2021

    by Zacks Equity Research

    Companies in The News Are: CAT,SIRI,OSTK,MRK

    Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales

    by Zacks Equity Research

    Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.

    Alkermes (ALKS) Q3 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.

    Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View

    by Zacks Equity Research

    Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.

    Mark Vickery headshot

    Jobless Claims, Q3 GDP Lower than Expected

    by Mark Vickery

    Another big day for data ahead of the opening bell this morning, with some good news and a few disappointments.

    Q3 GDP Grew Lower than Expected

    by Zacks Equity Research

    Q3 GDP Grew Lower than Expected

    Merck (MRK) Q3 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Merck (MRK) delivered earnings and revenue surprises of 13.64% and 5.90%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Sweta Killa headshot

    Healthcare ETFs in Focus as Q3 Earnings Unfold

    by Sweta Killa

    The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.